Drug Transporter (DT) Information

General Information of DT
DT ID DTD0031
Gene Name SLCO2B1
Protein Name Organic anion transporting polypeptide 2B1
Gene ID
11309
UniProt ID
O94956
TCDB ID
2.A.60.1.20
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; SLC21A9; SLCO2B1; Solute carrier family 21 member 9; Solute carrier organic anion transporter family member 2B1
DT Family Organo Anion Transporter (OAT) Family ;
Tissue Specificity Isoform 1 has it's highest expression inbrain, it is the major form expressed in duodenum, kidney,placenta, and skeletal muscle. Isoform 3 predominates in liver.
Function This Na(+)-independent transporter mediates the transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Disease(s) Diabetes [ICD-11: 5A10-5A14]
Dry eye disease [ICD-11: 9A79]
Dyslipidaemias [ICD-11: 5C8Z]
High blood pressure [ICD-11: BA00]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Medical abortion [ICD-11: JA00.1]
Open angle glaucoma [ICD-11: 9C61]
Pulmonary arterial hypertension [ICD-11: BB01.0]
Renal cell carcinoma [ICD-11: 2C90]
Endogenous Substrate(s) Organoanions
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          29 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Abiraterone acetate
 Approved Drug Info Prostate cancer 2C82 [1]
Aliskiren fumarate
 Approved Drug Info High blood pressure BA00 [2]
Atorvastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [3]
Bosentan
 Approved Drug Info Pulmonary arterial hypertension BB01.0 [4]
Cerivastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [5]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [6]
Digoxin
 Approved Drug Info Arrhythmias BC60-BC9Z [7]
Dinoprostone
 Approved Drug Info Medical abortion JA00.1 [8]
Eltrombopag
 Approved Drug Info Idiopathic thrombocytopenic purpura 3B64.10 [9]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [10]
Etoposide
 Approved Drug Info Testicular cancer 2C80 [11]
Fexofenadine
 Approved Drug Info Allergic rhinitis CA08.0 [12]
Fluvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [10]
Glibenclamide
 Approved Drug Info Diabetes 5A10-5A14 [13]
L-glutamic acid
 Approved Drug Info Schizophrenia 6A20 [14]
Latanoprost
 Approved Drug Info Open angle glaucoma 9C61 [15]
Latanoprostene bunod
 Approved Drug Info Renal cell carcinoma 2C90 [15]
Lifitegrast
 Approved Drug Info Dry eye disease 9A79 [16]
Mesalazine
 Approved Drug Info Recurrent ventricular fibrillation BC71.1 [17]
Montelukast
 Approved Drug Info Asthma CA23 [18]
Pemetrexed
 Approved Drug Info Malignant pleural mesothelioma 2C26.0 [19]
Pitavastatin
 Approved Drug Info Primary hyperlipidemia and mixed dyslipidemia 5C8Z [20]
Pitavastatin calcium
 Approved Drug Info Dyslipidaemias 5C8Z [21]
Pravastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [22]
Ritonavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [23]
Rocuronium
 Approved Drug Info Muscle relaxant XM31L2 [7]
Rosuvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [24]
Sulfasalazine
 Approved Drug Info Rheumatoid arthritis FA20 [25]
Telmisartan
 Approved Drug Info High blood pressure BA00 [26]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Benzylpenicillin
 Phase 4 Drug Info Gram-positive bacteria infections 1A00-1H0Z [8]
M17055
 Phase 3 Drug Info Diuretic vasodilator BA00 [27]
Talinolol
 Phase 1 Drug Info Gastrointestinal motility disorder DE2Z [28]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Scutellarin
 Preclinical Drug Info Cerebrovascular ischaemia 8B1Z [29]
Sodium taurocholate
 Preclinical Drug Info Type 2 diabetes 5A11 [22]
Taurocholic acid
 Terminated Drug Info Type 2 diabetes 5A11 [22]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:          21 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Atorvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 2.84 microM [30]
Atorvastatin Approved Drug Info Madin-Darby canine kidney cells (MDCKII)-OATP2B1 Km = 0.2 microM [31]
Bosentan Approved Drug Info Chinese hamster ovary (CHO) cells-OATP2B1 Km = 202 microM [4]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 1.56 microM [32]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 7.14 microM [13]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 8.09 microM [22]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 10.2 microM [10]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 12.5 microM [33]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 13.1 microM [22]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 20.9 microM [21]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 38.24 microM [30]
Estrone sulfate Approved Drug Info Human enterocyte-like 2 cells (Caco-2)-OATP2B1 Km = 1.81 microM [32]
Estrone sulfate Approved Drug Info Oocytes-OATP2B1 Km = 6.3 microM [34]
Fluvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 0.75 microM [10]
Glibenclamide Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 6.26 microM [13]
Mesalazine Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 188.9 microM [17]
Pitavastatin calcium Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 1.17 microM [21]
Pravastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 2250 microM [22]
Rosuvastatin Approved Drug Info Human cervical cancer cell line (Hela)-OATP2B1 Km = 2.4 microM [35]
Rosuvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 6.42 microM [24]
Telmisartan Approved Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 1.09 microM [26]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Sodium taurocholate Preclinical Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 71.8 microM [22]
Taurocholic acid Terminated Drug Info Human embryonic kidney cells (HEK293)-OATP2B1 Km = 71.8 microM [22]
Bromsulphthalein Investigative Drug Info Oocytes-OATP2B1 Km = 0.7 microM [34]
References
1 The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May;77(13):1303-1311.
2 Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011 May;71(5):718-26.
3 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
4 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
5 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
6 Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One. 2011;6(5):e20372.
7 Drug Interactions in Infectious Diseases.
8 Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
9 Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
10 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
11 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
12 The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93.
13 Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23.
14 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
15 The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
16 Clinical Pharmacology and Biopharmaceutics review(s)
17 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
18 Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
19 Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42.
20 Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet. 2011;26(2):171-9.
21 Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
22 Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
23 pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22.
24 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
25 Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
26 Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
27 Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res. 2007 Jan;24(1):90-8.
28 Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9.
29 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
30 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
31 Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006 Dec;80(6):607-20.
32 Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos. 2006 Aug;34(8):1423-31.
33 Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9.
34 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
35 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.